Dominick T. Gattuso

I'll research this attorney's professional background before drafting.

Let me verify a few more specifics — PTAB involvement, the Saul Ewing period, and key case outcomes.

Dominick T. Gattuso — Patent Litigation Practice Summary

Focus areas. Gattuso's patent work is heavily concentrated in Hatch-Waxman/ANDA pharmaceutical litigation, where he appears for generic and follow-on manufacturers against branded plaintiffs in the District of Delaware — including tafamidis (Pfizer v. Dexcel/Cipla/Hikma/Aurobindo), sacubitril/valsartan (In re Entresto MDL), cabazitaxel (Sanofi-Aventis v. Mylan/Dr. Reddy's-type matters), fingolimod (Novartis v. Sun Pharma), and Exelixis v. MSN. He also handles non-pharma patent matters spanning telecommunications, computer hardware/software, and mechanical/consumer products (e.g., Whirlpool v. Electrolux, FedEx v. Roambee, Tracer Imaging v. Mixtiles). His firm bio lists intellectual property, corporate, and complex commercial litigation, with stated experience in patent, trade secret, and trademark cases for both plaintiffs and defendants.

Side preference. He works both sides but skews defense: five of eight tracked appearances are for defendants versus three for plaintiffs. The defense work is overwhelmingly generic-drug side in ANDA cases; the plaintiff-side matters include representation of operating companies asserting patents (e.g., Whirlpool's 2025 Delaware infringement suit against Electrolux), not NPE/PAE assertion campaigns. Nothing in the record indicates a plaintiff-side PAE practice.

Firm context and role. He is a partner at Heyman Enerio Gattuso & Hirzel LLP in Wilmington, Delaware (the successor to Proctor Heyman, where he was previously a member). Six of eight tracked appearances are at that firm; two are attributed to other firms (Phillips, McLaughlin & Hall; Saul Ewing). Note a sourcing caveat: the Saul Ewing entry is from the tracked docket data and I could not independently verify a Saul Ewing affiliation from public professional profiles — a similarly named attorney (Kimberly L. Gattuso) appears at Saul Ewing in unrelated filings, so the entry should be confirmed before relying on it. His role in Delaware practice is predominantly as local counsel (six of eight tracked appearances; one lead counsel), acting as Delaware counsel to out-of-state lead firms such as Winston & Strawn.

Notable matters and appellate experience. Verifiable highlights include: Exelixis v. MSN Laboratories (D. Del.), where he filed the defendants' November 2024 Federal Circuit notice of appeal from judgment on declaratory-judgment invalidity claims; the consolidated Pfizer tafamidis action (C.A. No. 23-879), in which he is Delaware counsel to Hikma and where a five-day bench trial was set for April 2026; FedEx v. Roambee (D. Del.), an IPR-driven stay dispute in which he argued for the defendant; Meda Pharmaceuticals v. Apotex (Dymista patents), which proceeded to a 2017 bench trial; and In re Entresto Patent Litigation, where he handled discovery and deposition practice. He also appeared for Watson Laboratories in the Bayer v. Watson appeal. Outcomes were mixed; I did not find a publicly reported trial win attributable to him individually, so no verdict claims should be made.

PTAB/IPR experience. No evidence of Gattuso appearing as counsel of record in IPR/PGR proceedings was identified. His PTAB-related work appears indirect — managing parallel district court litigation alongside third-party IPRs (e.g., the Qualcomm IPRs in FedEx v. Roambee) rather than serving as IPR counsel. This should be treated as unverified absence rather than confirmed non-participation.

Bar and education. Admitted in Delaware (1997) and to the U.S. District Court for the District of Delaware (1998); J.D., cum laude, Widener University (1997); B.A., Wilkes University (1992). No USPTO patent bar registration was found in the sources reviewed. Clerked for Judges Henry duPont Ridgely and N. Maxson Terry, Delaware Superior Court (1997–98).